THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC

REPORT ON CONSOLIDATED FINANCIAL STATEMENTS (with supplementary information)

YEARS ENDED DECEMBER 31, 2025 AND 2024

Maner Costerisan

TABLE OF CONTENTS

Page

INDEPENDENT AUDITOR'S REPORT 1-3

CONSOLIDATED FINANCIAL STATEMENTS

Statements of Financial Position 4
Statements of Activities and Changes in Net Assets 5
Statements of Functional Expenses 6-7
Statements of Cash Flows 8

Notes to Consolidated Financial Statements 9-22

SUPPLEMENTARY INFORMATION 23

Consolidating Statement of Financial Position 24
Consolidating Statement of Activities and Changes in Net Assets 25
Schedule of Functional Expenses for The Hope Foundation, Inc. 26
Schedule of Functional Expenses for SWOG Clinical Trials Partnerships, LLC 27

Maner Costerisan

2425 E. Grand River Ave.,
Suite 1, Lansing, MI 48912

2851 Charlevoix Dr SE #210,
Grand Rapids, MI 49546

☎ 517.323.7500

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of the
The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC

Opinion

We have audited the accompanying consolidated financial statements of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC, which comprise the consolidated statements of financial position as of December 31, 2025 and 2024, and the related consolidated statements of activities and changes in net assets, functional expenses, and cash flows for the years ended December 31, 2025 and 2024, and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC as of December 31, 2025 and 2024, and the changes in their net assets and their cash flows for the years ended December 31, 2025 and 2024 in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC's ability to continue as a going concern within one year after the date that the consolidated financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.

- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Supplementary Information

Our 2025 audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary information, as identified in the table of contents, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such supplementary information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The supplementary information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such supplementary information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated June 9, 2026, on our consideration of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC's internal control over financial reporting and on our tests of their compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC's internal control over financial reporting and compliance.

Maner Costerisan PC

Lansing, Michigan
June 9, 2026

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
DECEMBER 31, 2025 AND 2024

	2025	2024
ASSETS		
Current assets		
Cash and cash equivalents	$ 3,387,517	$ 5,593,560
Accounts receivable, net of allowance	3,907,868	2,729,491
Promises to give	46,000	3,000
Prepaid expenses	189,457	180,656
Investments	56,365,508	53,354,960
Total current assets	63,896,350	61,861,667
Property and equipment, less accumulated depreciation	54,180	65,038
Operating lease right-of-use assets	565,502	688,128
TOTAL ASSETS	$ 64,516,032	$ 62,614,833
LIABILITIES AND NET ASSETS		
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	$ 3,796,414	$ 6,472,967
Public funds - site/study liability	436,332	530,987
Deferred revenue	6,628	6,628
Current portion of operating lease liabilities	131,783	122,626
Assets held for others	11,991,430	14,002,075
Total current liabilities	16,362,587	21,135,283
Operating lease liabilities, less current portion	433,719	565,502
TOTAL LIABILITIES	16,796,306	21,700,785
NET ASSETS		
Without donor restrictions	46,160,989	39,463,206
With donor restrictions	1,558,737	1,450,842
TOTAL NET ASSETS	47,719,726	40,914,048
TOTAL LIABILITIES AND NET ASSETS	$ 64,516,032	$ 62,614,833

See notes to consolidated financial statements.

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
CONSOLIDATED STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS
YEARS ENDED DECEMBER 31, 2025 AND 2024

	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
REVENUE AND SUPPORT						
Contributions of cash and other financial assets	$ 99,976	$ 705,407	$ 805,383	$ 109,308	$ 665,692	$ 775,000
Administrative fees	14,323,891	-	14,323,891	11,723,609	-	11,723,609
Investment return, net	6,574,917	-	6,574,917	4,527,689	-	4,527,689
Public funds (federal awards)	5,237,075	-	5,237,075	5,372,693	-	5,372,693
Non-public funds for services	2,334,272	-	2,334,272	2,128,305	-	2,128,305
Other income	89,718	-	89,718	90,844	-	90,844
Net assets released from restrictions	597,512	(597,512)	-	525,791	(525,791)	-
TOTAL REVENUE AND SUPPORT	29,257,361	107,895	29,365,256	24,478,239	139,901	24,618,140
EXPENSES						
Program services	19,996,098	-	19,996,098	20,425,379	-	20,425,379
Management and general	2,219,041	-	2,219,041	2,212,390	-	2,212,390
Fundraising	344,439	-	344,439	182,275	-	182,275
TOTAL EXPENSES	22,559,578	-	22,559,578	22,820,044	-	22,820,044
CHANGE IN NET ASSETS	6,697,783	107,895	6,805,678	1,658,195	139,901	1,798,096
NET ASSETS						
Beginning of year	39,463,206	1,450,842	40,914,048	37,805,011	1,310,941	39,115,952
End of year	$ 46,160,989	$ 1,558,737	$ 47,719,726	$ 39,463,206	$ 1,450,842	$ 40,914,048

See notes to consolidated financial statements.

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED DECEMBER 31, 2025

	Program Services	Management and General	Fundraising	Total
Salaries and related				
Salaries	$ 3,651,753	$ 1,396,962	$ 128,645	$ 5,177,360
Retirement	322,060	126,053	11,319	459,432
Other employee benefits	610,643	221,932	19,966	852,541
Payroll taxes	266,943	100,526	9,409	376,878
Total salaries and related	4,851,399	1,845,473	169,339	6,866,211
Grants awarded	1,894,924	-	-	1,894,924
Trial related expenses	10,394,185	-	-	10,394,185
Office	57,393	16,597	924	74,914
Occupancy	88,553	67,627	-	156,180
Travel	547,880	5,414	7,819	561,113
Meetings and conferences	1,373,804	-	-	1,373,804
Staff and board development	-	15,325	826	16,151
Insurance	-	21,371	-	21,371
Advertising	-	410	-	410
Information technology	130,763	35,548	-	166,311
Telecommunications	18,510	7,516	568	26,594
Accounting fees	-	43,250	-	43,250
Legal fees	-	1,925	-	1,925
Other professional fees	554,448	31,830	145,689	731,967
Dues and subscriptions	-	72,177	19,274	91,451
Bank fees	-	16,691	-	16,691
Depreciation	3,861	6,997	-	10,858
Miscellaneous	80,378	30,890	-	111,268
TOTAL EXPENSES	$ 19,996,098	$ 2,219,041	$ 344,439	$ 22,559,578

See notes to consolidated financial statements.

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED DECEMBER 31, 2024

	Program Services	Management and General	Fundraising	Total
Salaries and related				
Salaries	$ 3,618,588	$ 1,333,644	$ 104,080	$ 5,056,312
Retirement	319,555	121,215	8,154	448,924
Other employee benefits	600,792	238,691	15,015	854,498
Payroll taxes	286,740	87,705	7,869	382,314
Total salaries and related	4,825,675	1,781,255	135,118	6,742,048
Grants awarded	2,675,213	-	-	2,675,213
Trial related expenses	9,674,514	-	-	9,674,514
Office	65,156	35,081	940	101,177
Occupancy	97,601	66,305	-	163,906
Travel	603,277	41,787	-	645,064
Meetings and conferences	1,510,666	-	-	1,510,666
Staff and board development	-	26,222	2,891	29,113
Insurance	-	19,093	-	19,093
Advertising	-	813	-	813
Information technology	71,945	20,457	-	92,402
Telecommunications	21,059	8,306	646	30,011
Accounting fees	-	41,700	-	41,700
Legal fees	-	46,792	-	46,792
Other professional fees	741,136	24,858	1,813	767,807
Dues and subscriptions	-	43,451	629	44,080
Bank fees	-	19,270	-	19,270
Depreciation	3,861	6,996	-	10,857
Miscellaneous	135,276	30,004	40,238	205,518
TOTAL EXPENSES	$ 20,425,379	$ 2,212,390	$ 182,275	$ 22,820,044

See notes to consolidated financial statements.

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEAR ENDED DECEMBER 31, 2025

	2025	2024
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		
Cash flows from operating activities		
Change in net assets	$ 6,805,678	$ 1,798,096
Adjustments to reconcile change in net assets to net cash provided (used) by operating activities		
Depreciation	10,858	10,857
Realized and unrealized gain on investments	(4,596,143)	(2,264,708)
Changes in		
Accounts receivable, net of allowance	(1,178,377)	525,685
Promises to give	(43,000)	(3,000)
Prepaid expenses	(8,801)	(28,426)
Operating lease right-of-use assets	122,626	(354,248)
Accounts payable and accrued liabilities	(2,676,553)	3,206,732
Public funds - site/study liability	(94,655)	(209,160)
Operating lease liabilities	(122,626)	354,248
Assets held for others	(2,010,645)	(4,848,539)
Total adjustments	(10,597,316)	(3,610,559)
Net cash used by operating activities	(3,791,638)	(1,812,463)
Cash flows from investing activities		
Purchases of investments	(21,256,053)	(31,316,682)
Proceeds from sale of investments	22,841,648	32,298,071
Net cash provided by investing activities	1,585,595	981,389
NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(2,206,043)	(831,074)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		
Beginning of year	5,593,560	6,424,634
End of year	$ 3,387,517	$ 5,593,560

See notes to consolidated financial statements.

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - NATURE OF ORGANIZATION, RISKS, AND UNCERTAINTIES

The Hope Foundation, Inc. (the Foundation), operates primarily for scientific and educational purposes, and is funded principally by contributions and public funds in particular research, education, and awareness connected with cancer morbidity and mortality. The Foundation carries out these broad purposes primarily by supporting the work of SWOG (described below). The Foundation is a nonprofit corporation exempt from federal income taxation, organized in accordance with the laws of the State of Texas.

SWOG Clinical Trials Partnerships, LLC (CTP) is a limited liability company which is wholly owned by the Foundation. CTP acts as an agent in administering cancer research projects conducted by SWOG members that are funded by contracts with pharmaceutical companies and other non-federal sources. CTP receives a fee in exchange for the administrative services it provides in receiving and distributing funds under these contracts. CTP is a disregarded entity for federal income tax purposes and, accordingly, its activities are consolidated and reported on IRS Form 990 of The Hope Foundation, Inc. CTP is organized in accordance with the laws of the State of Texas.

The consolidated financial statement represent the consolidation of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC. These consolidated financial statements do not include the activities of an affiliate, SWOG.

SWOG (Southwest Oncology Group) is a cooperative group of independent institutions such as universities, hospitals, and other research organizations involved in the study of cancer, particularity in the areas of cancer morbidity and mortality and clinical trials of new cancer treatment drugs. SWOG is one of several cooperative groups sponsored by the National Cancer Institute. Cooperative groups differ in structure and in focus. Some groups study a specific type of cancer therapy, while others focus on a group of related cancers. The members of SWOG collaborate in conducting research, education, and public awareness activities related to many different adult cancer types.

The SWOG Operations Center is the central location for SWOG's clinical activities. The SWOG Operations Center activities include organizing SWOG member meetings, developing the design and protocol of cancer research studies, and improving the quality of data obtained in the studies.

The Foundation and CTP are collectively referred to as "the Organization".

The Foundation is exempt from federal income taxes under section 501(c)(3) of the Internal Revenue Code, except for tax on "Unrelated Business Income" as defined. No provision for income taxes is required.

In preparation of tax returns, tax positions are taken based on interpretation of federal, state and local tax laws. Management periodically reviews and evaluates the status of uncertain tax positions and makes estimates of amounts, including interest and penalties, ultimately due or owed. No amounts have been identified, or recorded, as uncertain tax positions. Federal, state and local tax returns generally remain open for examination by the various taxing authorities for a period of three to four years.

Due to the nature of the research within SWOG and the designation in the Foundation bylaws that a majority of board members must be SWOG members, the Foundation does on occasion award peer reviewed grants to institutions that employ certain board members, and these members may act as principal investigators of awarded funds.

NOTE 1 - NATURE OF ORGANIZATION, RISKS, AND UNCERTAINTIES (continued)

The Organization participates in various grant funded programs, which are subject to audit by grantor agencies and could generate expenditure disallowance under terms of the grants. Any disallowed claims, including amounts already used, may constitute a liability to the Organization. Management maintains that any liability for reimbursement of grant funds to a grantor agency resulting from an audit would not be material to the consolidated financial statements.

The process of preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the use of estimates and assumptions regarding certain types of assets, liabilities, revenues and expenses. Such estimates primarily relate to unsettled transactions and events as of the date of the consolidated financial statements. Accordingly, upon settlement, actual results may differ from estimated amounts.

The Organization is required to disclose significant concentrations of credit risk regardless of the degree of such risk. Financial instruments which potentially subject the Organization to concentrations of credit risk consist principally of cash and cash equivalents, investments and accounts receivable. The Organization follows a policy of placing its cash and cash equivalents with various FDIC insured financial institutions. Although such cash and investment balances may exceed the federally insured limits at certain times during the year and at year-end, they are, in the opinion of management, subject to minimal risk.

In addition, the Organization recognizes an allowance for credit losses at the time a receivable is recorded based on management's estimate of expected credit losses, historical write-off experience, and current account knowledge, and adjusts this estimate over the life of the receivable as needed. The Organization evaluates the aggregation and risk characteristics of a receivable pool and develops loss rates that reflect historical collections, current forecasts of future economic conditions over the time horizon the Organization is exposed to credit risk, and payment terms or conditions that may materially affect future forecasts.

The Organization performs ongoing credit evaluations of its third-parties' financial condition whenever deemed necessary. The Organization evaluates and maintains, if necessary, an allowance for credit losses based on the expected collectability of all accounts receivable, which takes into consideration an analysis of historical credit losses, specific third-parties creditworthiness and current economic trends. Management believes that the Organization's concentration of credit risk is limited because of the number of receivable balances, their credit quality, account balances, and geographic diversification.

The Organization evaluates events and transactions that occur after the year end for potential recognition or disclosure in the consolidated financial statements. These subsequent events have been considered through June 9, 2026, which is the date the consolidated financial statements were available to be issued.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The accompanying consolidated financial statements are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Principles of Consolidation

The consolidated financial statements represent the consolidation of The Hope Foundation, Inc. and SWOG Clinical Trials Partnerships, LLC. The appropriate significant intercompany transactions and balances have been eliminated in consolidation.

Cash and Cash Equivalents

The Organization considers liquid investments with maturities of three months or less as cash equivalents.

Promises to Give

The Organization reports unconditional promises to give as revenue (net realizable value) in the period received. Promises to give are evaluated for collectability and discounted when appropriate.

Accounts Receivable and Credit Losses

The Organization is exposed to credit losses primarily through third-parties for services provided. Accounts receivable represent the Organization's unconditional right to consideration in exchange for services that the Organization has provided to the third-parties. Accounts receivable are recorded when invoices are issued and are presented on the consolidated statement of financial position at the amount management expects to collect. Management provides for probable uncollectible amounts through credit losses expense and an adjustment to the allowance for credit losses. The Organization's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of third-parties trade accounts receivable. Due to the short-term nature of such receivables, the estimated accounts receivable that may not be collected is based on the aging of the accounts receivable balances.

The Organization evaluates contract terms and conditions, economic and industry risk, third-parties credit worthiness, and may require prepayment to mitigate risk of loss. Specific allowance amounts are established to record the appropriate provision for third-parties that have a higher probability of default. The Organization monitors changes to the receivables balance on a timely basis, and balances are written off as they are determined to be uncollectible after all collection efforts have been exhausted. See Note 1 regarding concentrations of credit risk.

Currently, management has determined the value of an allowance for credit losses is immaterial and recording of such balance is not considered necessary.

Beginning and ending balances for accounts receivable are reported as follows for the year ended December 31:

	2025	2024
Beginning of year	$ 2,729,491	$ 3,255,176
End of year	$ 3,907,868	$ 2,729,491

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Property and Equipment

Purchases of property and equipment are recorded at cost and are depreciated over the estimated useful lives using the straight-line method. Costs of maintenance and repairs are charged to expense when incurred. Property and equipment with a cost of $3,000 or more and a useful life greater than one year are capitalized.

Investments

Investment purchases are recorded at cost, or if donated, at fair value on the date of donation. Thereafter, investments are reported at their fair values in the consolidated statement of financial position. Net investment return is reported in the consolidated statement of activities and changes in net assets and consists of interest and dividend income, realized and unrealized capital gains and losses, less external and direct internal investment expenses.

Assets Held for Others

The Organization acts as agent in administering cancer research projects conducted by SWOG members that are funded by contracts or agreements with pharmaceutical companies and nonprofit organizations. As the agent in these contractual arrangements, the Organization receives cash advances, invoices and collects amounts from the pharmaceutical companies, makes payments to SWOG members and other clinical trial participant organizations conducting the research, and performs other administrative and accounting functions.

Deferred Revenue

The Organization records deferred revenue when cash payments are received or due in advance of the Organization's performance. Beginning and ending balances for deferred revenue is reported as follows for the year ended December 31:

	2025	2024
Beginning of year	$ 6,628	$ 6,628
End of year	$ 6,628	$ 6,628

Leases

The Organization determines whether an arrangement is or contains a lease at inception. On the commencement date, operating leases are recorded as operating lease right-of-use (ROU) assets in the consolidated statement of financial position while finance leases are recorded as finance lease ROU assets. Lease liabilities represent the Organization's contractual obligation to make lease payments over the lease term.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Leases (continued)

For operating leases, the lease liability is measured as the present value of the lease payment over the lease term using either the rate implicit in the lease, if it is determinable, or a risk-free rate if the implicit rate is not determinable. Operating ROU assets are calculated as the present value of the remaining lease payment plus unamortized initial direct costs and prepayments of rent, less any unamortized lease incentives. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Organization has elected to not recognize a ROU asset and lease liability for leases with an initial term of 12 months or less but includes the expenses associated with short term leases in the consolidated statement of activities and changes in net assets.

For finance leases, the lease liability is measured as the present value of the lease payments over the lease term using the rate implicit in the lease, if it is determinable, or a risk-free rate if the implicit rate is not determinable. The lease liability is then increased to reflect interest on the liability and decreased to reflect the lease payment. Interest on the lease liability is determined each period during the lease term as the amount that results in a constant period discount rate on the remaining balance of the liability. The ROU asset is determined consistent with the methodology of operating leases and is subsequently offset with any accumulated amortization and any accumulated impairment losses. Amortization on the ROU asset is recognized over the period from the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term except for leases with a purchase option for which the Organization believes purchase of the asset is expected to be exercised. For assets to be acquired under such purchase options the ROU asset is amortized over the expected life consistent with the Organization's policy for similar property and equipment. The Organization does not maintain any finance leases for the year-end December 31, 2025 and 2024.

The Organization has elected to utilize a risk-free rate as the discount rate when determining the present value of remaining lease payments for both operating and financing leases. Additionally, the Organization has elected to not separate non-lease components from lease components and, instead, to account for each separate lease component and the related non-lease component as a single lease component.

For any related party leasing agreements, the Organization has elected to use written terms and conditions for determining whether a lease exists and, if so, the classification and accounting for that lease.

Net Assets

Net assets, revenues, gains and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets without Donor Restrictions - Net assets available for use in general operations and not subject to donor or grantor restrictions.

Net Assets with Donor Restrictions - Net assets subject to donor (or grantor) imposed restrictions. Some donor restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor restrictions are perpetual in nature, where the donor stipulates that resources are maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition of long-lived assets are recognized as revenue when the assets are placed in service. Donor restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, or when the stipulated purpose has been accomplished.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition

Administration Fees

Administrative fees are derived from agency transactions where CTP administers cancer research projects by SWOG, funded by pharmaceutical companies and other non-federal resources. Performance obligations related to administrative fees are transferred to the customer over time. Principle terms of revenue recognition are over the term of the contract as the Organization satisfies the promised obligations as milestones are achieved in the clinical trials. Payment is due when each milestone is completed, therefore, contract receivables may exist at year-end. The contract terms are straightforward and do not involve significant judgement in the timing or amount of revenue recognized. Milestones are specified in each contract. The Organization's contracts for administrative fees do not contain variable consideration and contract modifications are generally minimal.

Public Funds

The Organization receives grant and contract revenue from federal sources for cancer research. Revenue associated with the direct costs of sponsored programs is generally recognized as the related costs are incurred. The Organization records revenue without donor restrictions upon its recovery of direct and indirect costs applicable to those sponsored programs that provide for the full or partial reimbursement of such costs. Most grants awarded to the Organization by government agencies are conditional contributions. The principal condition attached to these awards is that the Organization must incur costs in accordance with the grant contracts. Payments are received after costs are incurred.

Non-Public Funds for Services

The Organization receives non-public funds revenue from pharmaceutical companies and other non-federal sources. Performance obligations related to conducting particular research, education, and awareness connected with cancer morbidity and mortality is transferred to the customer over time as reimbursable costs are incurred. Therefore, the Organization recognizes revenue when costs are incurred. Payment terms include a deposit before performance begins followed by cost reimbursements. Therefore, contract liabilities and contract receivables may exist at year-end.

Contribution Revenue

Contributions of cash and other assets received without donor stipulations are reported as revenue and net assets without donor restrictions. Gifts received with a donor stipulation that limits their use are reported as revenue and net assets with donor restrictions. When a donor-stipulated time restriction ends, or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statement of activities and changes in net assets as net assets released from restrictions.

Donations of property and equipment are recorded as support at their estimated fair value at the date of donation. Contributions of land, buildings, equipment, and other long-lived assets are reported as revenue and net assets without donor restrictions unless explicit donor stipulations specify how such assets must be used, in which case the gifts are reported as revenue and net assets with donor restrictions. Absent explicit donor stipulations for the time long-lived assets must be held, expirations of restrictions resulting in reclassification of net assets with donor restrictions as net assets without donor restrictions are reported when the long-lived assets are placed in service.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition (continued)

Unconditional contributions expected to be collected within one year are reported at their net realizable value. Unconditional contributions expected to be collected in future years are initially reported at fair value determined using the discounted present value of estimated future cash flows technique. The resulting discount is amortized using the level-yield method and is reported as contribution revenue.

Conditional contributions depend on the occurrence of a specified future and uncertain event to bind the donor and are recognized as assets and revenue when the conditions are substantially met, and the gift becomes unconditional.

The following schedule shows the Organization's revenues disaggregated according to the timing of transfer of goods or services for the year ended December 31:

	2025	2024
Contract revenue recognized over time		
Administrative fees	$ 14,323,891	$ 11,723,609
Non-public funds for services	2,334,272	2,128,305
Contributions of cash and other financial assets	805,383	775,000
Investment return, net	6,574,917	4,527,689
Public funds	5,237,075	5,372,693
Other income	89,718	90,844
Total revenue and support	$ 29,365,256	$ 24,618,140

Functional Allocation of Expenses

The costs of providing program and other activities have been reported in the consolidated statement of activities and changes in net assets. The consolidated statement of functional expenses presents the natural classification of expenses that are allocated to program or supporting functions of the Organization. Specific expenses that are readily identifiable to a single program or activity are charged directly to that function. Certain categories of expenses are attributable to more than one program or supporting function. Allocated expenses primarily consist of payroll and related, which are allocated by estimates of time and effort, as well as occupancy and depreciation expense, which are allocated by estimates of square-footage. All other allocated expenses utilize management's estimated use of resources.

NOTE 3 - LIQUIDITY AND AVAILABILITY

The Organization regularly monitors the availability of resources required to meet its operating needs and other contractual commitments, while also striving to maximize the investment of its available funds. For purposes of analyzing resources available to meet general expenditures over a 12-month period, the Organization considers all expenditures related to its ongoing program service activities as well as the conduct of services undertaken to support those activities to be general expenditures. In addition to financial assets available to meet general expenditures over the next 12 months, the Organization anticipates collecting enough revenue to cover general expenditures.

NOTE 3 - LIQUIDITY AND AVAILABILITY (continued)

The following reflects the Organization's financial assets as of December 31, which are deemed available for general expenditures within one year of the date of the consolidated statement of financial position. Amounts not available include donor-imposed restrictions and assets held for others.

	2025	2024
Cash and cash equivalents	$ 3,387,517	$ 5,593,560
Accounts receivable, net of allowance	3,907,868	2,729,491
Promises to give	46,000	3,000
Investments	56,365,508	53,354,960
Total financial assets	63,706,893	61,681,011
Less donor imposed restrictions	(1,558,737)	(1,450,842)
Less financial assets held for others	(11,991,430)	(14,002,075)
Financial assets available to meet cash needs for general expenditures within one year	$ 50,156,726	$ 46,228,094

NOTE 4 - INVESTMENTS

Accounting standards establish a hierarchy that prioritizes the inputs to valuation techniques giving the highest priority to readily available unadjusted quoted prices in active markets for identical assets (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements) when market prices are not readily available or reliable. The three levels of the hierarchy are described below:

Level 1: Quoted prices in active markets for identical securities.

Level 2: Prices determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk and others.

Level 3: Prices determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable or deemed less relevant (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect the Organization's own assumptions about the factors market participants would use in pricing an investment, and would be based on the best information available.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

NOTE 4 - INVESTMENTS (continued)

Following is a description of the valuation methodologies used to determine how an asset is measured at fair value. There have been no changes in the methodologies used at December 31, 2025.

Mutual Funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Organization are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value (NAV) and to transact at that price. The mutual funds held by the Organization are deemed to be actively traded.

Limited Partnerships and Limited Liability Companies: The values of the limited partnerships and limited liability companies are calculated based on net asset value per share (or its equivalent) provided by the investment manager.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Organization believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following is a market value summary by the level of the inputs used in evaluating the Organization's assets carried at fair value at December 31. The inputs or methodology used for valuing securities may not be an indication of the risk associated with investing in those securities.

	2025	2024
Investments measured at fair value		
Level 1 measurement		
Mutual funds		
Equity	$ 25,802,948	$ 22,807,058
Fixed income	20,797,809	21,168,198
Total investments measured at fair value	46,600,757	43,975,256
Investments measured at net asset value		
Limited partnerships		
Hedge fund	3,960,439	3,723,494
Limited liability company	5,804,312	5,656,210
Total investments measured at net asset value	9,764,751	9,379,704
Total investments	$ 56,365,508	$ 53,354,960

NOTE 4 - INVESTMENTS (continued)

The following shows the redemption terms for investments measured at net asset value as of December 31, 2025:

Investment	Value	Redemption Frequency	Redemption Period
PIMCO Tactical Opportunities Offshore Fund Limited Partnership	$ 2,688,271	Limited (1)	95 business days
Parametric Defensive Equity Fund, LLC Performance	3,567,018	Monthly	5 business days
GQG Partners Emerging Markets Equity Fund	1,272,168	Monthly	5 business days
Partners Group Private Equity II Limited Partnership	2,237,294	Limited (1)	95 business days
	$ 9,764,751		

(1) PIMCO liquidity is limited with 2-year hard lock and 20% investor-level gate.

The following shows the redemption terms for investments measured at net asset value as of December 31, 2024:

Investment	Value	Redemption Frequency	Redemption Period
PIMCO Tactical Opportunities Offshore Fund Limited Partnership	$ 2,568,151	Limited (1)	95 business days
Parametric Defensive Equity Fund, LLC Performance	3,571,925	Monthly	5 business days
GQG Partners Emerging Markets Equity Fund	1,155,343	Monthly	5 business days
Partners Group Private Equity II Limited Partnership	2,084,285	Limited (1)	95 business days
	$ 9,379,704		

(1) PIMCO liquidity is limited with 2-year hard lock and 20% investor-level gate.

There are no unfunded commitments pertaining to the investments measured at net asset value.

NOTE 4 - INVESTMENTS (continued)

Investment return consists of the following for the years ended December 31:

	2025	2024
Interest and dividends	$ 2,148,571	$ 2,419,586
Realized gain	718,727	6,065,653
Unrealized gain (loss)	3,877,416	(3,800,945)
Investment fees	(169,797)	(156,605)
Investment return, net	$ 6,574,917	$ 4,527,689

NOTE 5 - PROPERTY AND EQUIPMENT

Property and equipment at December 31 consist of the following:

	Useful Life (in years)	2025	2024
Furniture and equipment	3 - 7	$ 304,024	$ 304,024
Leasehold improvements	3 - 7	59,315	59,315
		363,339	363,339
Less accumulated depreciation		(309,159)	(298,301)
Total net property and equipment		$ 54,180	$ 65,038

NOTE 6 - RETIREMENT PLANS

The Organization provides for two contributory, salary reduction type tax-deferred annuity plans administered under section 403(b) of the Internal Revenue Code. Employees are eligible to participate in the employer contribution upon employment. Participants receive a matching employer contribution, based on a percentage of their employee contribution, which is currently 200% of employee deferral up to 5% of employee compensation subject to contribution limitations. The Organization recognized contribution expenses of $459,432 and $448,924 during the year ended December 31, 2025 and 2024, respectively.

NOTE 7 - LEASE COMMITMENTS

The Organization leases its administrative offices, the SWOG operations center under non-cancelable operating leases. Those leases are categorized as operating right-of-use assets on the consolidated statement of financial position. The operating lease for the administrative office matures February 2028 with monthly estimated payments of $2,883 over the life of the lease. The operating lease for the SWOG operations center matures April 2030 with monthly estimated payments ranging from $9,562 to $11,046 over the life of the lease.

Supplemental information relating to the lease agreements for the year ended December 31, 2025 and 2024, are as follows:

	2025	2024
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	$ 151,571	$ 162,031
Weighted-average remaining lease term in years for operating leases	4.0	5.0
Weighted-average discount rate for operating leases	4.6%	4.6%

Operating lease expense is recognized in the following categories on the consolidated statement of functional expenses for the year ended December 31, 2025 and 2024:

	2025	2024
Occupancy expense	$ 156,180	$ 163,906

Future minimum payments under operating leases are as follows:

Year Ending December 31,	
2026	$ 154,992
2027	158,516
2028	133,319
2029	131,293
2030	44,184
Total undiscounted cash flows	622,304
Less: present value discount	(56,802)
Total operating lease liabilities	$ 565,502
Current portion of operating lease liabilities	$ 131,783
Operating lease liabilities, less current portion	433,719
Total operating lease liabilities	$ 565,502

NOTE 8 - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions released during the year ended December 31, 2025 and 2024, consists of the following:

	2025	2024
Adolescent Young Adult	$ -	$ (17)
Accrual Enhancement Funds - CTP Trials	6,438	-
Breast Committee	2,782	150,000
CRA Continuing Education	55,901	9,738
Dr. Nicholas Vogelzang	6,842	4,473
Early Stage Investigators	49,149	25,000
Group Meeting Support	119,000	70,000
GU Uro-Oncology Investigators	-	1,338
Innovation Working Group	-	1,943
John Crowley Award	1,884	(4,568)
Lymphoma Committee Support	9,217	-
Meyskens Endowed Lectureship	727	-
MU NCORP Program	62,500	(201)
Melanoma Prevention Working Group	627	-
Patient Advocacy	24,000	-
Quality Assurance and Education	10,155	-
Recruitment and Retention Committee	94,108	57,290
Robert Livingston	1,620	885
Robert Winn Leadership Award	6,457	4,250
S0819 Investigator Education	13,398	-
S0819 Accrual Enhancement	3,601	-
S1207 Accrual	27,769	-
S1400 Accrual	279	-
S1616 Site Payments	-	95,874
SEED	89,578	17,099
SWOG Leadership Development	-	92,687
SWOG Stats and Operations	11,480	-
	$ 597,512	$ 525,791

NOTE 8 - NET ASSETS WITH DONOR RESTRICTIONS (continued)

Net assets with donor restrictions for the year ended December 31, 2025 and 2024 , consists of the following:

	2025	2024
Adolescent Young Adult (AYA)	$ 116,775	$ 116,775
Accrual Enhancement Funds - CTP Trials	43,005	-
Breast Committee	-	2,782
CRA Continuing Education	215,152	102,533
Charles Coltman Fellowship	21	21
Direct Study Support	280,000	125,000
Dr. Nicholas Vogelzang	9,936	15,526
Early Stage Investigators	12,169	27,625
Group Meeting Support	6,000	-
GU Fellowship	111,209	111,209
GU Uro-Oncology Investigators	20,696	20,696
Innovation Working Group	20,115	20,115
John Crowley Award	22,721	14,605
Lymphoma Committee Support	119,279	128,496
Melanoma Prevention Working Group	-	627
Meyskens Endowed Lectureship	54,765	50,492
Modality and Imaging Network	68,254	68,254
MU NCORP Program	3,541	66,041
Patient Advocacy	-	24,000
Quality Assurance and Education	77,481	87,637
Recruitment and Retention Committee	62,242	146,350
Robert Livingston	68,802	62,923
Robert Winn Leadership Award	133,293	49,750
S0819 Accrual Enhancement	-	3,601
S0819 Investigator Education	-	13,398
S0820 CPP PACES	98	98
S1007 BCRF	11,881	11,881
S1207 Accrual	-	27,768
S1400 Accrual	28,456	28,735
SEED	50,000	89,578
SWOG Breast Committee Fellowship	10,000	10,000
SWOG Leadership Development	12,742	12,742
SWOG Stats and Operations	-	11,480
SWOG Trial Support	104	104
	$ 1,558,737	$ 1,450,842

SUPPLEMENTARY INFORMATION

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
CONSOLIDATING STATEMENT OF FINANCIAL POSITION
DECEMBER 31, 2025

	The Hope Foundation, Inc.	SWOG Clinical Trials Partnerships, LLC	Eliminations	Consolidated Total
ASSETS				
Current assets				
Cash and cash equivalents	$ 1,454,766	$ 1,932,751	$ -	$ 3,387,517
Accounts receivable, net of allowance	933,227	2,974,641	-	3,907,868
Promises to give	46,000	-	-	46,000
Prepaid expenses	189,457	-	-	189,457
Investments	44,448,394	11,917,114	-	56,365,508
Intercompany receivables	317,345	-	(317,345)	-
Total current assets	47,389,189	16,824,506	(317,345)	63,896,350
Property and equipment, less accumulated depreciation	28,249	25,931	-	54,180
Operating lease right-of-use assets	421,145	144,357	-	565,502
TOTAL ASSETS	$ 47,838,583	$ 16,994,794	$ (317,345)	$ 64,516,032
LIABILITIES AND NET ASSETS				
LIABILITIES				
Current liabilities				
Accounts payable and accrued liabilities	$ 1,583,665	$ 2,212,749	$ -	$ 3,796,414
Public funds - site/study liability	436,332	-	-	436,332
Intercompany payables	-	317,345	(317,345)	-
Deferred revenue	-	6,628	-	6,628
Current portion of operating lease liabilities	96,634	35,149	-	131,783
Assets held for others	-	11,991,430	-	11,991,430
Total current liabilities	2,116,631	14,563,301	(317,345)	16,362,587
Operating lease liabilities, less current portion	324,511	109,208	-	433,719
TOTAL LIABILITIES	2,441,142	14,672,509	(317,345)	16,796,306
NET ASSETS				
Without donor restrictions	43,838,704	2,322,285	-	46,160,989
With donor restrictions	1,558,737	-	-	1,558,737
TOTAL NET ASSETS	45,397,441	2,322,285	-	47,719,726
TOTAL LIABILITIES AND NET ASSETS	$ 47,838,583	$ 16,994,794	$ (317,345)	$ 64,516,032

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
CONSOLIDATING STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS
YEAR ENDED DECEMBER 31, 2025

	The Hope Foundation, Inc.			SWOG Clinical Trials Partnerships, LLC			Eliminations	Consolidated		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	Without Donor Restrictions	With Donor Restrictions	Total
REVENUE AND SUPPORT										
Contributions of cash and other financial assets	$ 2,183,284	$ 705,407	$ 2,888,691	$ -	$ -	$ -	$ (2,083,308)	$ 99,976	$ 705,407	$ 805,383
Administrative fees	-	-	-	14,323,891	-	14,323,891	-	14,323,891	-	14,323,891
Investment return, net	5,627,004	-	5,627,004	947,913	-	947,913	-	6,574,917	-	6,574,917
Public funds (federal awards)	5,237,075	-	5,237,075	-	-	-	-	5,237,075	-	5,237,075
Non-public funds for services	2,334,272	-	2,334,272	-	-	-	-	2,334,272	-	2,334,272
Other income	89,718	-	89,718	-	-	-	-	89,718	-	89,718
Net assets released from restrictions	597,512	(597,512)	-	-	-	-	-	597,512	(597,512)	-
TOTAL REVENUE AND SUPPORT	16,068,865	107,895	16,176,760	15,271,804	-	15,271,804	(2,083,308)	29,257,361	107,895	29,365,256
EXPENSES										
Program services	8,955,343	-	8,955,343	13,124,063	-	13,124,063	(2,083,308)	19,996,098	-	19,996,098
Management and general	1,131,649	-	1,131,649	1,087,392	-	1,087,392	-	2,219,041	-	2,219,041
Fundraising	344,305	-	344,305	134	-	134	-	344,439	-	344,439
TOTAL EXPENSES	10,431,297	-	10,431,297	14,211,589	-	14,211,589	(2,083,308)	22,559,578	-	22,559,578
CHANGE IN NET ASSETS	5,637,568	107,895	5,745,463	1,060,215	-	1,060,215	-	6,697,783	107,895	6,805,678
NET ASSETS, beginning of year	38,201,136	1,450,842	39,651,978	1,262,070	-	1,262,070	-	39,463,206	1,450,842	40,914,048
NET ASSETS, end of year	$ 43,838,704	$ 1,558,737	$ 45,397,441	$ 2,322,285	$ -	$ 2,322,285	$ -	$ 46,160,989	$ 1,558,737	$ 47,719,726

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
SCHEDULE OF FUNCTIONAL EXPENSES FOR THE HOPE FOUNDATION, INC.
YEAR ENDED DECEMBER 31, 2025

	Program Services	Management and General	Fundraising	Total
Salaries and related				
Salaries	$ 3,516,290	$ 655,224	$ 128,645	$ 4,300,159
Retirement	309,375	56,593	11,319	377,287
Other employee benefits	592,236	134,227	19,966	746,429
Payroll taxes	257,175	47,044	9,409	313,628
Total salaries and related	4,675,076	893,088	169,339	5,737,503
Grants awarded	1,894,924	-	-	1,894,924
Office	57,393	7,477	924	65,794
Occupancy	88,553	24,239	-	112,792
Travel	534,742	5,414	7,685	547,841
Meetings and conferences	1,340,476	-	-	1,340,476
Staff and board development	-	11,711	826	12,537
Insurance	-	14,516	-	14,516
Advertising	-	410	-	410
Information technology	130,763	19,058	-	149,821
Telecommunications	18,510	5,464	568	24,542
Accounting fees	-	29,600	-	29,600
Legal fees	-	1,925	-	1,925
Other professional fees	130,667	24,330	145,689	300,686
Dues and subscriptions	-	49,446	19,274	68,720
Bank fees	-	13,175	-	13,175
Depreciation	3,861	906	-	4,767
Miscellaneous	80,378	30,890	-	111,268
TOTAL EXPENSES	$ 8,955,343	$ 1,131,649	$ 344,305	$ 10,431,297

THE HOPE FOUNDATION, INC. AND SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
SCHEDULE OF FUNCTIONAL EXPENSES FOR SWOG CLINICAL TRIALS PARTNERSHIPS, LLC
YEAR ENDED DECEMBER 31, 2025

	Program Services	Management and General	Fundraising	Total
Salaries and related				
Salaries	$ 135,463	$ 741,738	$ -	$ 877,201
Retirement	12,685	69,460	-	82,145
Other employee benefits	18,407	87,705	-	106,112
Payroll taxes	9,768	53,482	-	63,250
Total salaries and related	176,323	952,385	-	1,128,708
Trial related expenses	10,394,185	-	-	10,394,185
Contributions	2,083,308	-	-	2,083,308
Office	-	9,120	-	9,120
Occupancy	-	43,388	-	43,388
Travel	13,138	-	134	13,272
Meetings and conferences	33,328	-	-	33,328
Staff and board development	-	3,614	-	3,614
Insurance	-	6,855	-	6,855
Information technology	-	16,490	-	16,490
Telecommunications	-	2,052	-	2,052
Accounting fees	-	13,650	-	13,650
Other professional fees	423,781	7,500	-	431,281
Dues and subscriptions	-	22,731	-	22,731
Bank fees	-	3,516	-	3,516
Depreciation	-	6,091	-	6,091
TOTAL EXPENSES	$ 13,124,063	$ 1,087,392	$ 134	$ 14,211,589